Pfizer Presents New Evidence of IBRANCE palbociclib Effectiveness in HR HER2 Metastatic Breast Cancer Patients in Four RealWorld Studies at ESMO Congress 2019

Pfizer Presents New Evidence of IBRANCE (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019

First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials Pfizer Inc. (NYSE: PFE)...

More From BioPortfolio on "Pfizer Presents New Evidence of IBRANCE (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019"